First human tests: how does a bad liver handle this new drug?
NCT ID NCT06916078
Summary
This is an early safety study to see how a new drug called lepodisiran behaves in people with healthy livers compared to those with mild, moderate, or severe liver problems. Researchers will give a single injection and then carefully measure how much of the drug gets into the blood and how long it stays, while also checking for side effects. The goal is to gather basic information on safety and how the drug is processed, which is a standard first step before testing if the drug works to treat a disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American Research Corporation at Texas Liver Institute
RECRUITINGSan Antonio, Texas, 78215, United States
Contact Phone: •••-•••-••••
Contact
-
CRU Early Phase Unit
RECRUITINGKistarcsa, H-2143, Hungary
Contact Phone: •••-•••-••••
Contact
-
Clinical Pharmacology of Miami
RECRUITINGMiami, Florida, 33014-3616, United States
Contact Phone: •••-•••-••••
Contact
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.